Enanta Pharma (NASDAQ: ENTA) reported Q2 EPS of $0.20, versus $0.61 reported last year. Revenue for the quarter came in at $39.6 million versus the consensus estimate of $40.88 million.

“Enanta remains in a strong financial position that allows us to continue to execute and advance our planned clinical objectives, with important data readouts by the end of next quarter,” said Jay R. Luly, Ph.D. President and CEO, Enanta Pharmaceuticals. “We expect to announce three clinical milestones in the coming months − topline data from our Phase 2a human challenge study of EDP-938 for RSV by mid-year, followed by initiation of a Phase 1 study of EDP-514, our first HBV molecule, in the third quarter, and then Phase 2a data from our study of EDP-305 in NASH by the end of the third quarter.”

For earnings history and earnings-related data on Enanta Pharma (ENTA) click here.